Kimba, a developer of an AI-powered sleep technology system that uses real-time biometric data and automated scent therapy to improve sleep quality, raised $6.5 million in funding led by Selva Ventures, a leading consumer health and wellness investor whose portfolio includes fast-growing brands such as Grüns and OneSkin.
Kimba said the funding will support its commercial launch and accelerate its efforts to redefine the sleep technology category by moving beyond passive tracking toward active, personalized sleep improvement.
“Kimba was built on a simple but powerful idea that sleep shouldn’t just be measured; it should be improved,” said Ben Fuxbruner, Founder and CEO of Kimba.
“We’re introducing a fundamentally new approach that uses scent to work with the brain during sleep, helping people achieve deeper, more restorative rest without drugs or disruption. For me, it was life-changing,” added Ben Fuxbruner.
Kimba is developing a personalized sleep profile for each person and proprietary water-based and plant-derived scent formulations tailored to their sleep patterns and preferences.
Throughout the night, Kimba continuously monitors biometric signals including breathing patterns, movement, heart rate variability, and stress indicators through built-in sensors in the Kimba device and integrations with wearables, including WHOOP, Oura, Apple Watch, Fitbit, and Garmin.
Using adaptive AI, the system analyzes biometric data in real time to understand the body’s changing sleep state and deliver precisely timed, personalized scent cues throughout the night to optimize sleep depth, continuity, and recovery. The result is a seamless, drug-free, non-invasive sleep solution designed to actively improve sleep quality without pills, grogginess, or dependency.
Digital health companies, including sleep technology startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Sychedelic, a neurotechnology startup developing closed-loop wearable neuromodulation systems designed to help individuals relax, sleep, and focus better, raised $3.5 million in seed funding to launch its wearable neuromodulation headphones.
In another deal, Osteoboost Health, a developer of FDA-cleared wearable therapy for osteopenia clinically proven to reduce bone loss in the spine, raised $8 million in a fresh financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of its medical device for low bone density.